Comparison of liposomal amphotericin B alone and in combination with flucytosine in the treatment of non‐HIV Cryptococcal meningitis: A nationwide observational study

Cryptococcal meningitis (CM) is an opportunistic infectious disease that occurs in immunocompromised hosts, not only in patients living with HIV, but also in patients without HIV. The evidence regarding the treatment for CM in patients without HIV is mainly found in small retrospective studies and is extremely limited.

[1]  Duolao Wang,et al.  Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis , 2022, The New England journal of medicine.

[2]  W. Powderly,et al.  Presentation and Mortality of Cryptococcal Infection Varies by Predisposing Illness: A Retrospective Cohort Study. , 2019, The American journal of medicine.

[3]  Duolao Wang,et al.  Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa , 2018, The New England journal of medicine.

[4]  Thomas Lumley,et al.  Fitting Regression Models to Survey Data , 2017 .

[5]  J. D. Beckham,et al.  Cryptococcosis in solid organ transplant recipients , 2015, Current opinion in infectious diseases.

[6]  K. Ashizawa,et al.  Clinical features of pulmonary cryptococcosis in non-HIV patients in Japan. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  H. Yasunaga,et al.  Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Kari Lock Morgan,et al.  Balancing Covariates via Propensity Score Weighting , 2014, 1609.07494.

[9]  J. Farrar,et al.  Combination antifungal therapy for cryptococcal meningitis. , 2013, The New England journal of medicine.

[10]  J. Perfect,et al.  Comparison and Temporal Trends of Three Groups with Cryptococcosis: HIV-Infected, Solid Organ Transplant, and HIV-Negative/Non-Transplant , 2012, PloS one.

[11]  Til Stürmer,et al.  The role of the c‐statistic in variable selection for propensity score models , 2011, Pharmacoepidemiology and drug safety.

[12]  W. El-Sadr,et al.  Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Perfect,et al.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Senn,et al.  A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. , 2003, Clinical therapeutics.

[15]  L. Letenneur,et al.  Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Diasio,et al.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. , 1987, The New England journal of medicine.

[17]  M. Tashiro,et al.  Executive Summary of JSMM Clinical Practice Guidelines for Diagnosis and Treatment of Cryptococcosis 2019. , 2020, Medical mycology journal.

[18]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[19]  P. Pappas.  Cryptococcal infections in non-HIV-infected patients. , 2013, Transactions of the American Clinical and Climatological Association.